TORONTO--(BUSINESS WIRE)--Morganti & Co., P.C., a cross border shareholder’s rights law firm, has commenced a shareholder class action lawsuit against Intellipharmaceutics International Inc. (“IPCI”) for publishing investor documents containing misrepresentations of material fact about its New Drug Application for Rexista to the U.S. Federal Drug Agency between February 29, 2016, and July 26, 2017.
The shareholders allege that these misrepresentations resulted in the market price and value of IPCI's securities being artificially inflated or otherwise over-valued as reflected by a portion of the drop in the market price after the release of the corrective disclosures on July 26, 2017.
Investors that purchased IPCI’s securities listed on the Toronto Stock Exchange may have an opportunity to recover their financial losses. Investors are encouraged to contact Morganti & Co. to register their interest and determine their financial losses, if any. Investors will not be charged for this service.
About Morganti & Co.
You may learn more about Morganti & Co. online at www.morgantico.com. Since June 1999, Mr. Morganti has represented investors and is licensed to provide legal opinions about the Ontario Securities Act and the U.S. federal securities laws.
The Firm also represents investors against BP plc, Goldcorp Inc., FSD Pharmaceutics, Guyana Goldfields, Ithaca Energy Inc., Maxar Technologies Inc., Namaste Technologies Inc., and others.
You may contact Morganti & Co. at (647) 344-1900 or by email at email@example.com for further information. This press release may be considered attorney advertising in some jurisdictions under the applicable law and ethical rules.